COST-EFFECTIVENESS ANALYSIS OF CEFTRIAXONE-AZITHROMYCIN COMBINATION AND SINGLE LEVOFLOXACIN AS EMPIRICAL ANTIBIOTICS IN COMMUNITY-ACQUIRED PNEUMONIA INPATIENTS AT PERSAHABATAN HOSPITAL by Suratini, Sri et al.
Print - 0974-2441
PTMDS 2017 | The 1st Physics and Technologies in Medicine and Dentistry Symposium
COST-EFFECTIVENESS ANALYSIS OF CEFTRIAXONE-AZITHROMYCIN COMBINATION AND 
SINGLE LEVOFLOXACIN AS EMPIRICAL ANTIBIOTICS IN COMMUNITY-ACQUIRED PNEUMONIA 
INPATIENTS AT PERSAHABATAN HOSPITAL
SRI SURATINI1, RANI SAURIASARI1*, FIRZAWATI HAMADAH2, TRI KUSUMAENI3
1Department of Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia. 2Department of Health, Regional General 
Hospital Bekasi, Bekasi, Indonesia. 3Department of Pharmacy, Persahabatan Hospital, Jakarta, Indonesia. Email: rani@farmasi.ui.ac.id
Received: 21 April 2017, Revised and Accepted: 13 July 2017
ABSTRACT
Objective: Community-acquired pneumonia (CAP) is one of the most common infectious diseases. Its prevalence is especially concerning, as the 
disease severely impacts health and has a high mortality rate. Although antibiotics have been used to treat CAP, their use is often costly and inefficient. 
Thus, this study aimed to determine the cost-effectiveness of using ceftriaxone-azithromycin combination and single levofloxacin as empirical 
antibiotics to treat patients with CAP. Cost-effectiveness was analyzed by comparing the direct total medical cost to clinical effectiveness, which was 
indicated by the respective success rates in each treatment group.
Methods: This study was conducted at Persahabatan Hospital in Jakarta and employed an observational study design, where data were obtained 
retrospectively from the secondary data contained in medical records for 2014-2016. A total of 100 patients were included in the analysis, with 
64 patients using intravenous (iv) antibiotic ceftriaxone and oral azithromycin and 36 patients using iv single levofloxacin.
Results: The median costs of antibiotics were significantly different between the ceftriaxone-azithromycin group and the levofloxacin group: 
Rp.130.756 and Rp.286.952, respectively. The direct total medical cost in the ceftriaxone-azithromycin group (Rp.6.494.998) was higher than that 
of the single levofloxacin group (Rp.5.444.242). The success rate was 95.3% in the ceftriaxone-azithromycin group and 97.2% in the levofloxacin 
group, but there were no significant differences between the two groups. The medians for the length of stay (LOS) and length of stay antibiotic-related 
(LOSAR) measures in the levofloxacin group were 6 and 5 days, which were shorter than the LOS and LOSAR medians in the ceftriaxone-azithromycin 
group: 7 days and 6 days, respectively. The average cost-effectiveness ratio value in the levofloxacin group was 56.011% effectiveness lower than that 
of the ceftriaxone-azithromycin group, which was Rp.68.153% effectiveness.
Conclusions: Based on these results, it can be concluded that levofloxacin is more cost-effective than a combination of ceftriaxone-azithromycin for 
treating CAP.
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INTRODUCTION
In the transition of global epidemics from communicable diseases to 
non-communicable diseases, developing countries carry a double 
burden in health. Despite the conclusion of the millennium development 
goals era, developing countries continue to experience problems with 
communicable diseases such as diarrhea, tuberculosis, HIV/AIDS, and 
pneumonia. Community-acquired pneumonia (CAP) is one of the most 
common infectious diseases. Its prevalence is especially concerning 
because the disease causes severe health problems and has a high 
mortality rate. Moreover, treating the disease constitutes a significant 
financial burden because of the high costs of a health service, especially 
staying in the hospital, which represents 70-90% of the total medical 
cost [1].
The total medical cost for patients with pneumonia in 2005 in the 
United States of America was about $40 million, with $34 million 
reflecting direct cost [2]. Pneumonia is one of the seven most common 
causes of death in the US, where it is estimated that there are 4 million 
cases of CAP every year, resulting in 10 million doctor visits, 1 million 
cases of inpatient care, and 45000 deaths [3]. In Indonesia, pneumonia 
represents one of big ten conditions requiring inpatient care, with case 
proportions of 53.95% male and 46.05% female and a 7.6% crude 
fatality rate, which is higher than other diseases. According to Riskedas, 
in 2013, there was an increasing inclination of pneumonia period 
prevalence in all ages: From 2.1% in 2007 to 2.7% in 2013. The five 
provinces that had the highest pneumonia incidence and prevalence 
for all ages were East Nusa Tenggara (4.6% and 10.3%), Papua (2.6% 
and 8.2%), Central Sulawesi (2.3% and 5.7%), West Sulawesi (3.1% and 
6.1%), and South Sulawesi (2.4% and 4.8%) [4].
In Indonesia, the National Health Insurance (JKN) uses the Indonesia 
Case-based Groups (INA-CBG) payment system for higher level health-
care facilities. Hospitals are paid based on the INA-CBG tariffs, which 
reflect the mean cost spent for a diagnosis group. Community-acquired 
pneumonia is included in the INA-CBG group in the disease class of 
simple pneumonia and whooping cough. According to the data from 
Indonesia National Health Insurance, pneumonia is one of the ten 
highest costing inpatient care conditions for JKN. Antibiotics are integral 
for treating infectious diseases. Because of increasing health-care costs 
and limited resources, policymakers, and health-care personnel could 
benefit from a study examining the cost effectiveness of antibiotics. 
Pharmacoeconomic evaluation is done to analyze the cost effectiveness 
of antibiotics and to understand whether antibiotics provide a good 
treatment outcome at a minimal cost.
According to the Infectious Disease Society of America (IDSA), 
the American Thoracic Society (ITS), and the Indonesia Society of 
Respirology (PDPI), the antibiotics used for treating CAP during 
inpatient care are from the beta-lactam group and are combined 
with macrolide or single respiratory quinolone antibiotics [5]. In 
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Indonesia, for JKN service, there is a significant different in price 
between the two antibiotic choices. Thus, the pharmacoeconomic 
analysis is needed to determine the cost-effectiveness of each option. 
Bhavnani and Ambrose compared gemifloxacin quinolone antibiotics 
to ceftriaxone-clarithromycin combination antibiotics and found that 
gemifloxacin is more cost-effective than ceftriaxone-clarithromycin 
combination [6]. Dresser et al. compared gatifloxacin-quinolone 
antibiotics to ceftriaxone-macrolide combination antibiotics and also 
stated that the quinolone antibiotics were more cost-effective than the 
beta-lactam-macrolide combination antibiotics [7]. This study was 
performed at Persahabatan Hospital, which is a Class A Government 
General Hospital and National Referral Hospital for respiratory health 
located in East Jakarta. This study sought to determine the cost-
effectiveness of ceftriaxone-azithromycin combination and single 
levofloxacin as empirical antibiotics for the treatment of inpatients 
with pneumonia.
METHODS
This study is an observational study, where data were obtained 
retrospectively from secondary data (patients’ medical records). The 
results of this study are provided in descriptive and analytical forms. 
This study was conducted at Persahabatan Hospital. The participants 
in this study were patients who had been diagnosed with CAP, had 
received inpatient care, and had been given empirical antibiotic therapy, 
as written in their medical records from 2014 to 2016 in Persahabatan 
Hospital.
Samples were only chosen if the patients met the following inclusion 
criteria: (1) Patients who received inpatient care and main diagnosis 
of CAP. The diagnosis of pneumonia was made based on signs and 
symptoms as well as adjunctive examination such as laboratory 
results or Roentgen photos, (2) adult patients above 18 years old, (3) 
patients who received ceftriaxone-azithromycin combination or single 
levofloxacin as empirical antibiotics to treat their CAP, and (4) patients 
with National Health Insurance (JKN) who had done one therapy cycle 
(i.e., patient who were not forcibly discharged). Exclusion criteria 
included the following: (1) Pregnant patients, (2) patients with other 
infections, and (3) patients with incomplete medical records.
Univariate analysis was used to describe patients’ demographic 
data, which was then presented in tables. Bivariate analysis was 
used to understand patients’ characteristic differences in each 
empirical antibiotic group and determine the relationship between 
the independent variable and the dependent variable. To understand 
characteristic differences of age, gender, treatment class, and PSI class, 
chi-square test was used. To determine the effect of the independent 
variable on the dependent variable, a mean difference test was done 
in two groups using a t-test if the data distribution was normal and 
a Mann–Whitney test if the data distribution was not normal. To 
determine whether a relationship existed between the cofounding 
variable and the dependent variable, a Chi-square test was used. 
A logistic regression test was used to determine and predict the 
cofounding variables, including age, gender, accompanying diseases, 
degree of severity, and length of stay (LOS).
Cost-effectiveness was analyzed by determining the positions of the 
treatments under study on a cost-effectiveness diagram and comparing 
those positions with those of alternative treatments. The treatment cost 
of each group of antibiotics was compared by calculating the average 
cost-effectiveness ratio (ACER), which reflected the total direct medical 
cost spent by patients with CAP receiving inpatient care divided by 
antibiotic usage effectiveness or “success rate:”
Total direct medical costACER=
Success rate
Sensitivity analysis was done to determine how far cost changes 
or effectiveness used to calculate ACER can affect the conclusion. 
Sensitivity analysis for antibiotic cost-effectiveness was done by 
increasing and decreasing the variation by 10% and 25% of the total 
cost.
RESULTS
There were 432 medical records in 2014-2016 in which CAP had been 
diagnosed; however, only 100 patients met the inclusion criteria and 
were thus included in this study. Of these 100 patients, 64 patients 
received empirical antibiotic therapy of intravenous (iv) ceftriaxone 
combination and azithromycin while 36 patients were treated with the 
empirical antibiotic of iv levofloxacin.
Descriptive data of the participants are presented in Table 1. The median 
age of patients with CAP who received empirical antibiotic therapy 
using ceftriaxone-azithromycin combination or levofloxacin from 2014 
to 2016 was 59 years old; 50% of the patients were >60 years old. In 
the United States, it is estimated that there are around 5.2 million adult 
patients with CAP, and the majority of these individuals are above 
65 years old (4.200 out of every 100.000 people) [8]. In the Netherlands, 
45% of patients with CAP are above 65 years old [9]. Risk factors for 
CAP include old age and comorbidity. In geriatric populations, getting 
older is related to increased rates of contracting CAP, inpatient care, 
and death. Among around 1.1 million inpatients in hospitals due to 
pneumonia (including CAP) in 2007, 21% were 45-64 years old and 58% 
were 65 years old or older. To reduce CAP risks, the IDSA and the ITS 
consensus guidelines recommend that individuals above 50 years old 
receive annual vaccination with inactive influenza virus and individuals 
who are 65 years and older receive a pneumococcus vaccination [10].
In this study, there were 51 male patients (51%) and 49 female patients 
(49%), with 43.8% male and 56.3% female patients in the ceftriaxone-
azithromycin treatment group and 63.9% male and 36.1% female 
patients in the levofloxacin treatment group. This study consisted of 
patients with JKN at Persahabatan Hospital with a main diagnosis of 
CAP. According to the treatment class, there was no significant difference 
between the ceftriaxone-azithromycin group and the levofloxacin 
group, where Class III represented the most frequent treatment class: 
67% of the total patients. In the ceftriaxone-azithromycin group, there 
was 3.1% Class I patients, 23.4% Class II patients, and 73.4% Class III 
patients. In the levofloxacin group, there was 8.3% Class I patients, 
36.1% Class II patients, and 55.6% Class III patients.
The conditions that were most comorbid with CAP among the patients 
in this study were hypertension (29%) and diabetes mellitus (25%) 
followed by acute chronic failure (16%), heart failure (13%), chronic 
obstructive pulmonary disease (COPD) (9%), asthma (6%), stroke 
(6%), malignancy (3%), and liver disease (2%). Comorbidity is a risk 
factor in CAP. According to study by Torres et al., comorbid conditions 
including respiratory disease and chronic cardiovascular disease, 
cerebrovascular disease, Parkinson’s disease, epilepsy, dementia, 
dysphagia, chronic kidney or liver disease, and even HIV can increase 
the risk of CAP by 2-4 times [11]. In the geriatric population, chronic 
diseases (diabetes mellitus, COPD, cancer, heart failure disease, and 
chronic kidney disease), age, and immune system can give not only lead 
to the contraction of a pneumonia infection but also to the development 
of a pneumonia infection, resulting in poor health outcomes [12]. In 
this study, the effectiveness parameter is based on the success rate, the 
LOS, and the LOS antibiotic-related LOSAR (Table 2). The success rate 
reflects whether the antibiotic resulted in successful treatment. The 
treatment is a success if the patient was cured or experienced clinical 
improvement, and the treatment was a failure if the patients died. 
LOS was calculated as the total days from the patient’s first day at the 
hospital until discharge by doctor’s agreement due to being cured or 
experiencing clinical improvement. LOSAR was calculated as the total 
number of days patients received iv empirical antibiotics. Patients who 
were discharged at their own demand were excluded from this study.
The dosages given to the combination therapy group were 1×2 gr iv and 
1×3 gr iv of ceftriaxone and 1×500 mg per oral of azithromycin. The 
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dosage used for the levofloxacin group was 1×750 mg iv. According to 
the literature, a high dose of levofloxacin (750 mg), produces similar 
results but in a shorter time than a dosage of 500 mg, especially for fever 
alleviation. In the ceftriaxone-azithromycin group, there were 3 patients 
(4.7%) who died; in the levofloxacin group, 1 patient (2.8%) died. The 
survival or success rates in both groups were not statistically significant 
(95.3% and 97.2%, respectively). A journal review by Raz-Pasteur 
et al. (2015) stated that there is no significant difference between 
fluoroquinolone antibiotics and beta-lactam/macrolide in the total 
number of deaths: RR (95%, CI) 0.99 (0.70-1.40) [13]. A meta-analysis 
done by Skalsky et al. stated that there is no significant difference in the 
mortality rate between quinolone groups and monotherapy macrolide 
or combination with beta-lactam RR (1.03. 95%, CI: 0.63-1.68) [14].
To investigate the effect of LOS using PSI score, age, gender, total and 
type of comorbidity, chi-square test was used. As shown in the results 
in Table 3, there was a significant relationship between LOS and 
degree of severity (PSI class) (p=0.022). Meanwhile, the results did 
not show a significant relationship between LOS and age (p=0.840), 
total of comorbidity (p=0.665), gender (p=0.686), presence (present 
or not present) of diabetes mellitus comorbidity (p=0.665), presence 
(present or not present of hypertension comorbidity (p=0.824), 
presence (present or not present) of heart failure comorbidity 
(p=0.228), presence (present or not present) of stroke comorbidity 
(p=0.235), presence (present or not present) of asthma comorbidity 
(p=0.080), presence (present or not present) of COPD comorbidity 
(p=0.486), presence (present or not present) of acute kidney failure 
comorbidity (p=0.787), presence (present or not present) of heart 
disease comorbidity (p=0.508), and presence (present or not present) 
of malignancy comorbidity (p=1.000). Based on bivariate analysis, 
a multivariate analysis with logistic regression of the confounding 
factors was conducted with a p<0.25. The results showed that degree of 
severity, especially Classes IV and V PSI was significantly related to LOS 
(p=0.020, OR: 2.963 with 95%, CI: 1.185-7.409).
Table 1: Patients’ characteristics organized by empirical antibiotics treatment at Persahabatan Hospital from 2014 to 2016
Patient’s characteristics Total (n=100) Ceftriaxone iv and azithromycin (n=64) Levofloxacin iv (n=36) p‑value
Age (%)
18-39 years old 9 (9.0) 5 (7.8) 4 (11.1) 0.844
40-59 years old 41 (41.0) 27 (42.2) 14 (38.9)
>60 years old 50 (50.0) 32 (50.0) 18 (50.0)
Median 59 59 59
Range 19-85 19-85 19-84
Gender (%)
Male 51 (51.0) 28 (43.8) 23 (63.9) 0.063
Female 49 (49.0) 36 (56.3) 13 (36.1)
Degree of severity (%)
PSI score 83.2+26.7 83.5+28.9 82.6+22.5 0.870
PSI class score (%)
Class I ND ND ND 0.879
Class II 35 (35.0) 23 (35.9) 12 (33.3)
Class III 21 (21.0) 13 (20.3) 8 (22.2)
Class IV 43 (43.0) 27 (42.2) 16 (44.4)
Class V 1 (1.0) 1 (1.6) 0 (0)
Inpatient care class (%)
Class I 5 (5.0) 2 (3.1) 3 (8.3) 0.160
Class II 28 (28.0) 15 (23.4) 13 (36.1)
Class III 67 (67.0) 47 (73.4) 20 (55.6)
Comorbidity (%)
Diabetes mellitus 25 (25.0) 19 (29.7) 6 (16.7) 0.229
Hypertension 29 (29.0) 19 (29.7) 10 (27.8) 1.000
Heart failure 13 (13.0) 8 (12.5) 5 (13.9) 1.000
COPD 9 (9.0) 4 (6.3) 5 (13.9) 0.277
Asthma 6 (6.0) 1 (1.6) 5 (13.9) 0.022*
Stroke 6 (6.0) 4 (6.3) 2 (5.6) 1.000
Chronic kidney failure 16 (16.0) 13 (20.3) 3 (8.3) 0.158
Liver disease 2 (2.0) 2 (3.1) 0 (0.0) 0.535
Malignancy 3 (3.0) 2 (3.1) 1 (2.8) 1.000
Amount of comorbidity (%) 1.000
0-1 comorbidity 68 (68.0) 43 (67.2) 25 (69.4)
>2 comorbidity 32 (32.0) 21 (32.8) 11 (30.6)
PSI: Pneumonia severity index, ND: Not defined, p value: Significance value, p value>0.05 there is no significant difference between the two groups, COPD: Chronic 
obstructive pulmonary disease, *p<0.05, significant
Table 2: Effectiveness difference between the two treatment groups
Parameter Total (n=100) Ceftriaxone iv and azithromycin (n=64) Levofloxacin iv (n=36) p value
Success rate (total)
Heal 96 (96.0) 61 (95.3) 35 (97.2) 1.000
Dead 4 (4.0) 3 (4.7) 1 (2.8)
LOS (days)
Median 7 6 0.004*
Range 2-14 3-14 2-11
LOSAR (days)
Median 6 5 0.011*
Range 2-15 3-15 2-11
LOS: Length of stay, LOSAR: Length of stay antibiotic-related, *p<0.05, significant
 Suratini et al.                                Asian J Pharm Clin Res, Vol 10, Suppl 5, 2017,
 
121
Table 4 shows the cost component analysis from each treatment group. 
The two empirical antibiotics groups were significantly different 
in price. The price of ceftriaxone-azithromycin was less than that 
of levofloxacin. As known, the drugs supply in the National Health 
Insurance Scheme is organized based on a national e-catalog for drugs 
majority the e-catalog is an electronic information system that lists 
the drugs’ type, technical specification, and stock price from several 
suppliers. Based on the e-catalog, the price of infusion levofloxacin per 
unit is Rp.22.318 in DKI Jakarta while the price of injection ceftriaxone 
is Rp.3.300 and 1.888 for azithromycin; Table 4 demonstrates that there 
is significant difference between the two antibiotics in terms of price.
Other costs that were analyzed were room cost, doctor’s visit cost, 
drugs cost, adjunctive examination cost, and treatment cost. There was 
no significant difference between doctor’s visit costs, room cost, and 
treatment cost. The patients included in the group were from treatment 
Classes I-III, and the composition was not statistically significant 
between each class. In room cost analysis, there was no significant 
difference between the ceftriaxone-azithromycin group and the 
levofloxacin group. In adjunctive examination, there was a significant 
difference between each group. In the different treatment classes, there 
was a statistical difference in the tariffs of the room cost and doctor’s 
visit cost, but not in adjunctive examination. In this study, differences in 
adjunctive examination cost could have been affected by each group’s 
LOS, as patients required varying levels of adjunctive examination.
CER was done by comparing total cost (C) to effectiveness (E) in each 
treatment group. The result was interpreted as mean effectiveness 
per unit. The lower the cost was, the higher the effectiveness from the 
C/E ratio and the investment value obtained from that intervention 
was; therefore, this strategy is chosen [15]. The total cost reflected the 
total cost of each treatment median while effectiveness referred to the 
treatment success rate (cured or clinical improvement). The results of 
the CER calculation can be seen in Table 4. The calculation in Table 5 
shows that the ACER value of the ceftriaxone-azithromycin group is 
Rp.68.153% effectiveness, which is higher than the ACER value of the 
levofloxacin group, which was Rp.56.011% effectiveness. Therefore, 
levofloxacin is considered more cost-effective than ceftriaxone-
azithromycin combination.
A cost-effectiveness grid can be used to define cost-effectiveness. To 
understand a treatment or cost-effective service, cost and effectiveness 
should be calculated. If an alternative treatment is more effective and 
has a lower cost (cell G), is more effective but has the same cost (cell H), 
or has the same effectiveness and a lower cost (cell D), that treatment 
can be defined as cost-effective. However, if an alternative treatment is 
less effective and has a higher cost (cell C), has the same effectiveness 
but also has a higher cost (cell F), or has less effectiveness and the same 
cost (cell B), that drug is not considered cost effective (Table 6) [15].
The results of the sensitivity analysis show that choosing levofloxacin is 
sensitive to a 25% increase in cost, and this increase in cost yields a higher 
ACER result than the baseline ceftriaxone-azithromycin ACER value 
(Table 7). Choosing levofloxacin is sensitive to a 25% decrease in the cost 
of the ceftriaxone-azithromycin group, and this decrease in cost yields a 
lower ACER result in the levofloxacin group than the baseline ACER value.
DISCUSSION
This study examined the cost-effectiveness of ceftriaxone-
azithromycin combination and single levofloxacin as empirical 
Table 3: Bivariate analysis to determine the effects of 
confounding factors on LOS
Confounding LOS (<7 days) p‑value
n (%) n (%)
Degree of severity
Class II and III PSI 30 (53.6) 26 (46.4) 0.014*
Class IV and V PSI 12 (27.3) 32 (72.7)
Age
<60 years old 22 (44.0) 28 (56.0) 0.840
>60 years old 20 (40.0) 30 (60.0)
Gender
Male 20 (39.2) 31 (60.8) 0.686
Female 22 (44.9) 27 (55.1)
Total of comorbidity
<2 comorbidity 30 (44.1) 38 (55.9) 0.665
>2 comorbidity 12 (37.5) 20 (62.5)
Presence of diabetes mellitus
Not present 33 (44.0) 42 (56.0) 0.640
Present 9 (36.0) 16 (64.0)
Presence of hypertension
Not present 29 (40.8) 42 (59.2) 0.824
Present 13 (44.8) 16 (55.2)
Presence of CHF
Not present 39 (44.8) 48 (55.2) 0.228*
Present 3 (23.1) 10 (76.9)
Presence of stroke
Not present 38 (40.4) 56 (59.6) 0.235*
Present 4 (66.7) 2 (33.3)
Presence of asthma
Not present 37 (39.4) 57 (60.6) 0.080*
Present 5 (83.3) 1 (16.7)
Presence of COPD
Not present 37 (40.7) 54 (59.3) 0.486
Present 5 (55.6) 4 (44.4)
Presence of AKI
Not present 36 (42.9) 48 (57.1) 0.787
Present 6 (37.5) 10 (62.5)
Presence of malignancy
Not present 41 (42.3) 56 (57.7) 1.000
Present 1 (33.3) 2 (66.7)
Presence of heart disease
Not present 42 (42.9) 56 (57.1) 0.508
Present 0 (0.0) 2 (100.0)
AKI: Acute kidney failure, CHF: Congestive heart failure, COPD: Chronic 
obstructive pulmonary disease, p<0.05 and p<0.25 are included in the 
multivariate analysis, LOS: Length of stay
Table 4: Direct medical cost distribution between the two 
treatment groups







Rp. 130.756 Rp. 286.952 0.000*
Room cost Rp. 675.000 Rp. 570.428 0.334
Doctor’s visit cost Rp. 568.456 Rp. 502.779 0.703
Drugs cost Rp. 1.093.844 Rp. 1.012.074 0.239
Adjunctive 
examination cost
Rp. 2.232.492 Rp. 1.304.804 0.000*
Treatment cost Rp. 741.716 Rp. 791.961 0.977
Other cost Rp. 172.744 Rp. 383.851 0.071
Total direct medical 
cost
Rp. 6.494.988 Rp. 5.444.242 0.082
Table 5: ACER calculation of each antibiotic group
Empirical 
antibiotic type





Rp. 6.494.988 95.3 Rp. 68.153% 
effectiveness
Levofloxacin iv Rp. 5.444.242 97.2 Rp. 56.011% 
effectiveness
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antibiotics for treating inpatients with CAP. The cost-effectiveness 
analysis was done by comparing the direct total medical cost to 
effectiveness, which was determined by the success rate in each 
treatment group. In this study, there was a significant difference in 
LOS between the two groups. The median LOS in the levofloxacin 
group was 6 days, while the median LOS in the ceftriaxone-
azithromycin was 7 days. There was also a significant difference 
between the two groups in the LOSAR. The LOSAR median in the 
patients who received levofloxacin was 5 days, whereas the LOSAR 
median in the patients who received ceftriaxone-azithromycin was 
6 days. This is in agreement with a previous study by Lodise et al., 
who stated that there was a significant difference in the LOS between 
the beta-lactam-macrolide group and the fluoroquinolone group 
(LOS median was 6 days and 5 days, respectively) [16]. A study done 
by Querol-Ribelles et al. stated that the median LOS for levofloxacin 
was 5 days, while the median LOS for ceftriaxone-clarithromycin was 
6 days, but no significant difference was found [17]. According to a 
meta-analysis conducted by Vardakas et al., the LOS for patients who 
received fluoroquinolone was 1-2 days shorter than patients who 
received antibiotics of macrolide or beta-lactam or a combination of 
both [18].
Some studies have investigated the relation between length of 
treatment and degree of severity in patients with CAP. Menendez 
et al. found a positive relationship between LOS and PSI score, 
pleura effusion, and blood urea nitrogen concentration and found 
no correlation between LOS and age, gender, alcohol intake, smoking 
cigarettes, and comorbidity [19]. A study by Garau et al. also found a 
significant relationship between LOS and death as well as LOS and PSI 
score (especially in Classes IV and V PSI, positive blood culture, ICU 
admission, and alcohol consumption) in patients with CAP [20]. The 
results of the current study are in agreement with the two previous 
studies, as the current study found a significant relationship between 
LOS and PSI score (degree of severity) [14].
Cost analysis was done to understand the total cost components in 
both treatment groups [15]. The costs included in this study were 
antibiotic cost, total drugs cost, doctor’s visit cost, treatment cost, 
and adjunctive examination cost. These costs are categorized as direct 
medical costs, which refer to the costs counted most often and are 
used directly to provide treatment [15]. According to the results, the 
effectiveness of levofloxacin therapy is higher than that of ceftriaxone-
azithromycin, and the direct medical cost of levofloxacin is lower than 
that of ceftriaxone-azithromycin; therefore, in the cost-effectiveness 
grid, levofloxacin is in the dominant group. In this case, there is no need 
to calculate the ICER because it can be concluded that levofloxacin is 
more cost-effective.
This study has several limitations. First, this study was conducted 
retrospectively from medical records, thus limiting the total number 
of participants. Second, this study did not compare across treatment 
classes due to the minimal total sample. According to cost-effectiveness 
analysis, levofloxacin care (with an ACER value of Rp.56.011%) is 
more cost-effective than ceftriaxone and azithromycin combination 
antibiotics (with an ACER value of Rp.68.153% effectiveness) for 
treating inpatients with CAP.
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